Highlights

  • Pacific Edge secured a draft Medicare policy change covering Cxbladder Triage and Triage Plus, a major strategic milestone.
  • FY26 Revenue declined sharply due to Medicare non-coverage, though cost controls helped reduce cash burn.
  • The company raised fresh Capital and sees a clearer pathway to profitability through higher-Margin product adoption.

Overview

Cancer diagnostics company Pacific Edge Limited (NZX:PEB) delivered a challenging FY26 financial result, but the year ended with a major strategic breakthrough that could reshape its future outlook. Revenue fell sharply following the loss of Medicare coverage in April 2025, while lower test volumes weighed on overall financial performance. However, Pacific Edge has now secured draft Medicare coverage for its Cxbladder Triage and Triage Plus tests under a new Local Coverage Determination, marking a significant step toward reimbursement recovery. The inclusion of higher-priced Triage Plus improves unit Economics and strengthens the path to profitability. Combined with disciplined cost reductions and a successful capital raise, the company enters FY27 in a stronger strategic position focused on restoring growth and commercial execution.

Did Medicare Coverage Change the Outlook for Pacific Edge?

A key highlight for Pacific Edge was the publication of a draft Medicare policy covering Cxbladder Triage and Triage Plus for intermediate-risk hematuria patients, establishing hematuria evaluation as a reimbursable Medicare benefit for the first time. This is a major commercial win because Triage Plus carries a significantly higher reimbursement price than legacy products, improving profitability potential on each test sold. Pacific Edge can also begin claim-by-claim reimbursement while final policy approval is expected later in 2026. The development reduces a major uncertainty that has pressured the Business since Medicare coverage was withdrawn in 2025 and gives the company a clearer foundation to rebuild sales momentum in the US market.

Why Did Pacific Edge’s FY26 Financial Results Remain Under Pressure?

Despite the strategic Medicare progress, Pacific Edge’s FY26 financial performance remained weak due to the lingering impact of non-coverage and reduced US testing volumes. Operating Revenue fell to $11.5 million from $21.8 million a year earlier, while total test volumes declined as Medicare-related disruptions continued to affect Demand. Net loss widened to $35.8 million, reflecting lower revenue despite tighter cost controls. However, the company reduced expenses, lowered monthly cash burn in the second half, and strengthened Liquidity through a $25.4 million capital raising, with an additional retail offer underway. These measures are designed to support operations, product innovation, and commercial growth while Pacific Edge focuses on achieving Medicare reimbursement recovery and improving long-term profitability.